President and CEO
Sam Raha has served as president and chief executive officer and member of the board of directors at Myriad Genetics since April 2025. He is guided by Myriad’s mission to advance health and well-being for all, by focusing on the needs of patients and the healthcare providers who serve them. He joined Myriad in December 2023 as chief operating officer and played an integral role in shaping Myriad’s long-term growth strategy, while delivering new perspectives and expertise to advance business initiatives, operational excellence, and profitability.
Sam has more than 30 years of proven experience in the life sciences and diagnostics industry. Before joining Myriad, he was the president of Agilent’s Diagnostics and Genomics Group with overall responsibility for the Group’s strategy, innovation, and results. Prior to Agilent, he led marketing and product at Illumina, and before that was the VP and general manager of the TaqMan/qPCR business at Life Technologies.
Sam earned his MBA from Santa Clara University and has an undergraduate degree in molecular and cell biology from the University of California, Berkeley.
EVP Corporate and Business Development
Patrick Burke was promoted to EVP of Strategy and Innovation in May 2021, responsible for corporate development, Myriad’s companion diagnostics business, digital strategy and partnerships with large health systems and health care providers. In addition to these functions, he leads the executive strategy team and the development long term corporate strategy. Dr. Burke joined Myriad in 2001 and has more than 20 years of experience in the precision medicine and pharmaceutical industries. He received his PhD in Experimental Cell Biology from the University of Utah, School of Medicine and his BA in Molecular Biology from the University of California, San Diego.
Chief Legal Officer & Corporate Strategy Officer
Jennifer Fox, Chief Legal Officer & Corporate Strategy Officer, joined Myriad Genetics in September 2024. Prior to joining Myriad Genetics, she worked as the Executive Vice President of External Affairs for Emergent BioSolutions where she was responsible for overseeing legal functions, government and public affairs, communications, and ESG initiatives. Prior to that role, she held positions with Brinks, Gilson & Lione, Novozymes North America and GSK. She earned a Bachelor of Science in Biology from the University of Toledo, a Master of Science in Biochemistry also from the University of Toledo, and a J.D. from North Carolina Central University.
Chief Technology Officer
Raj Jampa joined Myriad Genetics in 2026 as chief technology officer, bringing more than 22 years of experience leading enterprise-scale technology transformation across global, highly regulated organizations. He is a strategic technology executive with deep expertise in driving digital, AI and operating model transformation to accelerate growth, improve productivity and strengthen organizational resilience.
Raj has a proven track record of aligning technology strategy with business priorities and measurable outcomes, serving as a trusted advisor to executive leadership and boards. Prior to joining Myriad, he held senior technology leadership roles at Agilent Technologies, Exact Sciences and Genomic Health, where he led large-scale transformation initiatives across enterprise platforms, digital capabilities and operating models. He is particularly recognized for modernizing technology infrastructure and scaling AI-enabled capabilities to support business transformation.
As chief technology officer, Raj leads Myriad’s technology strategy and execution, including advancing enterprise platforms, data and AI capabilities to improve efficiency, enhance customer experience and support the company’s next phase of growth and value creation.
Chief Scientific Officer
Dale Muzzey, Ph.D., is chief scientific officer of Myriad Genetics. He joined the company in April 2014. Previously, he was senior vice president of R&D. Before joining Myriad, he was a postdoctoral scholar at University of California, San Francisco, with a fellowship from the Damon Runyon Cancer Research Foundation. Dr. Muzzey received a B.A. with honors in Biochemical Sciences from Harvard University and a Ph.D. in Biophysics from Harvard University. His thesis research applied signal-processing techniques to cellular signal-transduction cascades to better understand how response dynamics revealed insight into network architecture.
Executive Vice President - Commercial
Vishal Sikri has served as the Executive Vice President – Commercial at Myriad Genetics since September 2026, where he oversees global commercial strategy and execution, including marketing, sales, product management, business development, and customer experience. He brings more than 25 years of leadership experience across diagnostics, genomics, and consumer health, with prior roles at NeoGenomics Laboratories and Invitae. Mr. Sikri holds an MBA from Loyola University of Chicago and an MSc from UW Madison.
Chief People Officer
Shereen Solaiman, chief people officer, joined Myriad Genetics in March 2023. She has more than twenty years of professional experience in the human resources field. Before joining Myriad, she was senior vice president and chief human resources officer at OhioHealth, where she drove business results through talent development at all levels. Shereen received her master’s degree in Public Administration from New York University and her bachelor’s degree in Journalism/Public Relations from Ohio University.
Chief Operating Officer
Mark Verratti has served as chief operating officer at Myriad Genetics since April 2025, where he is focused on driving growth through strengthening operations and customer experience. Previously, Mark served as chief commercial officer, responsible for accelerating commercial and marketing capabilities, gaining new customer insights, and enhancing demand generation. He joined Myriad Genetics in 2017 as president of Myriad’s Mental Health business, including the GeneSight® pharmacogenomics test.
With more than 25 years of experience leading large commercial organizations in the pharmaceutical and medical device industries, Mark has held senior and general management positions with Cyberonics/LivaNova leading teams in over 70 countries. He received a B.S. in Life Sciences with a minor in Physiology from Penn State University.
Chief Financial Officer
Ben Wheeler joined Myriad in December 2011 as assistant controller and has advanced through multiple leadership roles including vice president, corporate controller; senior vice president, accounting; senior vice president, finance & treasury; chief financial officer, operations; and, since 2025, chief financial officer.
With more than 15 years of progressive finance and accounting experience, Ben has a proven track record of driving business strategy during periods of operational change, turnaround, and mergers and acquisitions. He has consistently delivered results by improving profitability in capital and debt markets, managing risk through turnarounds, and maximizing cash flow at all stages of business growth.
He earned both his B.S. and MAcc from Brigham Young University.